Masitinib, a new experimental drug to treat Multiple Sclerosis, is being tested in Europe

While there have been a number of success stories for MS research in 2013, last year saw yet another round of therapies aimed at treating Relapsing-Remitting Multiple Sclerosis rejected by the FDA, mainly on the grounds that the current experimental drugs for the disease feature too many side effects and not enough efficacy. In the case of secondary progressive multiple sclerosis, there were even fewer achievements in the realm of drug development. However, one novel drug for the treatment of Multiple Sclerosis continues to be tested in Europe, offering new hope for treating the disease, particularly in its most progressive forms. Masitinib, an experimental drug therapy developed by AB Science in France, is currently recruiting for its Phase 2b/3 testing phase, after presenting positive results from its previous clinical trial phase, which completed in 2011. The clinical trial puts Masitinib up against a placebo for the treatment of both Primary Progressive and Relapse-Free Secondary Progressive Multiple Sclerosis, in order to ascertain the drug’s safety in patients and efficacy in curtailing the progression of the disease. The program of the clinical trial is a rigorous 96-Week, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled study, featuring two Parallel-groups for a dose of Masitinib 6 mg/kg/Day versus the placebo.
READ MORE